Fractyl Health Announces Pricing of Initial Public Offering
02 2월 2024 - 10:08AM
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company
focused on pioneering new approaches for the treatment of type 2
diabetes (T2D) and obesity, today announced the pricing of its
initial public offering of 7,333,333 shares of common stock at a
public offering price of $15.00 per share, for total gross proceeds
of approximately $110.0 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Fractyl Health. All of the common stock is being offered by
Fractyl Health. The offering is expected to close on February 6,
2024, subject to customary closing conditions. In addition, Fractyl
Health has granted the underwriters a 30-day option to purchase up
to an additional 1,099,999 shares of its common stock at the
initial public offering price less the underwriting discounts and
commissions.
Fractyl Health’s common stock is expected to begin trading on
the Nasdaq Global Market on February 2, 2024, under the ticker
symbol “GUTS.”
BofA Securities, Morgan Stanley and Evercore ISI are acting as
joint book-running managers.
A registration statement relating to the securities being sold
in the offering has been declared effective by the U.S. Securities
and Exchange Commission on February 1, 2024. This offering is being
made only by means of a prospectus. Copies of the final prospectus
relating to this offering may be obtained, when available, by
contacting: BofA Securities, Inc., Attention: Prospectus
Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North
Carolina 28255 or by email at dg.prospectus_requests@bofa.com;
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, NY 10014 or by email at
prospectus@morganstanley.com; or Evercore Group L.L.C. 55 East 52nd
Street, 35th Floor, New York, New York 10055, Attention: Equity
Capital Markets.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About Fractyl HealthFractyl Health is a
metabolic therapeutics company focused on pioneering new approaches
to the treatment of metabolic diseases, including T2D and obesity.
Despite advances in treatment over the last 50 years, T2D and
obesity continue to be rapidly growing drivers of morbidity and
mortality in the 21st century. Fractyl Health’s goal is to
transform metabolic disease treatment from chronic symptomatic
management to durable disease-modifying therapies that target the
organ-level root causes of disease. Fractyl Health is based in
Lexington, MA.
Forward-Looking StatementsThis press release
includes certain disclosures that contain "forward-looking
statements," including, without limitation, statements regarding
Fractyl Health’s expectations regarding the commencement of trading
of its shares on the Nasdaq Global Market, the completion and
timing of the closing of offering and the anticipated use of net
proceeds from the offering. Forward-looking statements are based on
Fractyl Health’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, risks and uncertainties related to the satisfaction
of customary closing conditions and the completion of the offering,
and the risks inherent in procedural therapy and gene therapy
development for metabolic diseases, including procedural method
optimization, lead candidate nominations, preclinical studies and
clinical studies. These and other risks and uncertainties are
described more fully in the section titled "Risk Factors" in the
final prospectus related to the offering to be filed with the U.S.
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Fractyl Health undertakes no duty to update such information except
as required under applicable law. 
Contacts Corporate ContactLisa Davidson,
Chief Financial Officerir@fractyl.com, 781.902.8800
Media ContactBeth Brett, Corporate
Communicationsbbrett@fractyl.com, 720.656.6544
Investor ContactStephen JasperGilmartin
Groupstephen@gilmartinir.com, 619.949.3681
Fractyl Health (NASDAQ:GUTS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Fractyl Health (NASDAQ:GUTS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024